



## Company Profile

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include AC5 Advanced Wound System, AC5 Topical Hemostat, AC5-G and AC5 Surgical Hemostat.<sup>1, 2</sup>

1. AC5-G and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
2. AC5 and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

## Management Team

### Dr. Terrence W. Norchi

President, Chief Executive Officer and Director

### Richard E. Davis

Chief Financial Officer

## Recent News

Thursday, October 22, 2020 - 07:50 AM

[Arch Therapeutics, Inc. to Present at the Virtual Investor KOL Roundtable](#)

Wednesday, October 14, 2020 - 07:50 AM

[Arch Therapeutics Announces Presentations on AC5 Advanced Wound System at the 2020 Symposium on Advanced Wound Care \(SAWC\) Fall](#)

Thursday, September 10, 2020 - 07:50 AM

[Arch Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15 at 12 PM ET](#)

Wednesday, August 26, 2020 - 07:50 AM

[Arch Therapeutics to Present at The LD 500 Virtual Conference on Tuesday,](#)

## Contact Information

### Arch Therapeutics, Inc.

235 Walnut Street  
Suite 6  
Framingham, MA 01702

## OTCQB: ARTH



Share Price	\$0.17
Volume	612.21k
Shares Outstanding	193,044,766
Market Cap	\$31.85m
52 Week High	\$0.30
52 Week Low	\$0.13

as of 10/28/2020

[September 1 at 1 PM ET](#)

Tuesday, August 11, 2020 - 08:01 AM

[Arch Therapeutics Novel Self-Assembling Agent, AC5-GTM, for Use in Endoscopic Procedures was Presented at the Society of American Gastrointestinal and Endoscopic Surgeons \(SAGES\) 2020 Annual Meeting](#)

## **DISCLAIMER**

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.